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INTRODUCTION
CD4+CD25+ T regulatory cells (Tregs) with the ability to
suppress the function of normal responder T cells were first
described by Sakaguchi et al. (1). Tregs are typically hypore-
sponsive to antigenic stimulation and able to suppress the
proliferation and activation of both CD4+ and CD8+ T cells,
thus resulting in allograft tolerance (2, 3). These suppressive
mechanisms include stimulation through the T-cell recep-
tor by specific antigen, direct cell to cell contact, signaling
by cytokines, such as Interleukin (IL)-10, IL-4 and transform-
ing growth factor-β , and signals via costimulatory molecules
such as CTLA-4, CD28 and glucocorticoid-induced TNF
receptor (4, 5). Studies in rodents have shown that Tregs can
also play a central role in allograft rejection in transplanta-
tion (6).
After transplantation, Tregs are usually found in recipient
lymphoid tissue and at the graft site (7, 8). Tregs in both sites
can block the initiation of an immune response against the
graft. Tregs, which represent approximately 5-10% of periph-
eral circulating CD4+ T cells in rodents and humans, have
also been isolated from the peripheral blood of recipients (9);
however, there is little information about the clinical signif-
icance of circulating Tregs in kidney transplantation. This
study aimed to evaluate the clinical significance of circulat-
ing Tregs in transplantation during the early posttransplant
period when the immunologic response between host and
graft is active and strong immunosuppression is needed to
prevent acute rejection. In our study, we evaluated the asso-
ciation between the frequency of circulating Tregs and clin-
ical parameters that may affect the level of Tregs. The results
of our study suggest that the frequency of circulating Tregs
is associated with types of immunosuppressants and rejec-
tion process during the early posttransplant period.
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Clinical Significance of Monitoring Circulating CD4
+CD25
+ Regulatory T
Cells in Kidney Transplantation during the Early Posttransplant Period
The CD4
+CD25
+ T regulatory cells (Tregs) play an important role in immune toler-
ance in experimental transplantation but the clinical significance of circulating Tregs
in the peripheral blood is undetermined. In 50 kidney transplant (KT) recipients, 29
healthy controls and 32 liver transplant (LT) recipients, the frequency of Tregs was
measured with flow cytometry before and after transplantation. In the KT recipients,
IL-10 secretion was measured with an enzyme-linked immunospot (ELISPOT) assay.
The median frequency of circulating Tregs before KT was similar to that in healthy
controls but significantly lower than that in LT patients before transplantation. The
frequency of Tregs was significantly decreased in patients with subclinical acute
rejection compared with those without subclinical acute rejection. Calcineurin inhibitors
(CNIs) and anti-CD25 antibody decreased the frequency of Tregs but mTOR inhibitor
did not. The frequency of donor-specific IL-10 secreting cells did not correlate with
the number of Tregs. The frequency of circulating Tregs in KT recipients is strong-
ly affected by CNIs and anti-CD25 antibody, and a low frequency of Tregs is asso-
ciated with subclinical acute rejection during the early posttransplant period.
Key Words : T-lymphocytes, Regulatory; Graft Rejection; Interleukin-10; Kidney Transplantation; Kidney Fail-
ure, Chronic
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Study population and control
Total of 50 consecutive kidney transplant (KT) recipients
were studied. As controls, 32 liver transplant (LT) recipients
and 29 healthy controls (HC, 19 males, mean age 44±13
yr) were included. All transplant recipients received an allo-
graft at the Kangnam St. Mary’s Hospital between January
2006 and January 2007. The clinical characteristics are shown
in Table 1. There were no significant differences among groups
except for recipient age. In KT recipients, the renal function
of the patients was excellent (serum creatinine 1.2±0.3 mg/
dL) at the time of protocol biopsy (n=42), however, the sub-
clinical AR (SCAR) showed in the 11 (26%) of 42 patients.
And one patient died with a functional graft 3 month after
transplantation because of cytomegalovirus infection. 
Study design
After receiving informed consents, peripheral blood sam-
ples were obtained in HC, KT and LT recipients. In kidney
transplantation, blood sample was withdrawn before trans-
plantation and 1, 2, and 8 weeks after transplantation. In liver
transplantation, blood sample was obtained before transplan-
tation and 1 and 2 weeks after transplantation. After trans-
plantation, peripheral blood was consequently drawn before
intake of immunosuppressant. Protocol biopsy was performed
at 14 days post transplant. 
Immunosuppressive regimens
All patients received intravenous methylprednisolone (1
g per day) on the day of transplantation, and then oral pred-
nisolone was tapered down to 30 mg/day on the fourth day
of transplantation. We divided the KT patients into 3 groups
according to the immunosuppression: FK group (n=28)
(Basiliximab+Prednisolone+FK506+MMF), CsA groups
(n=12) (Basiliximab+Prednisolone+CsA+MMF) and CsA/
mTORi groups (n=10) (Prednisolone+CsA+sirolimus/eve-
rolimus). Initial CsA dose was 10 mg/kg per day by oral
route, and target trough levels were 200-400 ng/mL in the
first 4 weeks and 100-200 ng/mL thereafter in the CsA based
immunosuppresion, 100-200 ng/mL in the first 4 weeks and
75-150 ng/mL thereafter in the CsA/everolimus group. Ini-
tial FK506 dose was 0.16 mg/kg per day by oral route, and
target trough levels were 10-15 ng/mL in the first 3 months.
Initial dose of MMF was 1.5 g/day, and dose was modified
based on adverse effects such as diarrhea or leucopenia. IL-2
receptor blocking antibody (anti-IL-2R Ab, Basiliximab)
was given to 40 patients (CsA or FK506 based immunesup-
pression) 4 hrs before and 3 days after renal transplantation.
Everolimus was administered 1.5 mg per day and sirolimus
was loaded 6 mg per day and then adjusted dose of 2 mg/day
was maintained with target trough level of 5-15 ng/mL. In
LT recipients, mycophenolate mofetil, cyclosporine, and pred-
nisolone were given as standard immunosuppression. 
Clinical parameters
The potential factors which may affect circulating Tregs
were included. The type of underlying disease of end stage
renal disease (ESRD), the number of HLA mismatch, panel
reactive antibody (PRA), the age and sex of donor and recip-
ients, subclinical acute rejection (AR), episode of BK virus
(BKV) and cytomegalovirus (CMV) infection), graft func-
tion and cyclosporine/FK506 serum concentrations were
evaluated. 
The diagnosis of CMV infection was made when copy num-
ber of by real time polymerase chain reaction (RT-PCR) is
more than 2,000 copies/mL or with tissue biopsy, and the
diagnosis of BKV infection was made when copy number of
RT-PCR is more than 10,000/mL in peripheral blood. Sub-
clinical rejection was defined as either borderline/suspicious
or acute subclinical rejection in patients with stable serum
creatinine values at the time of biopsy (10). A test for the panel
reactive antibody (PRA) was performed by ELISA PRA (LAT-
M, One-Lambda Inc, CA, U.S.A.). More than 20% of PRA
was regarded as positive PRA. Delayed graft function (DGF)
was defined as the need for dialysis during the first week
after transplantation. Graft failure was defined as returning
to dialysis.
Flow cytometric analysis
Peripheral blood lymphocytes were stained with CD4-
FITC (Dinona, Seoul, Korea) and CD25-PE-Cy7 (BD Phar-
mingen, San Diego, CA, U.S.A.). The percentages of CD4+-







Age (yr, mean±SD) 49±94 2 ±11 0.002
Male sex (%)  25 (78) 35 (70) 0.418
Donor 
Age (yr, mean±SD) 36±10 38±12 0.472
Male sex (%)  19 (59) 19 (38) 0.058
Donor source 0.078
LRD 32 (100) 45 (90)
DD - 5 (10)
Number of HLA mismatch 3.2±1.8 3.6±1.4 0.699
PRA (+) 5 (15.6) 7 (14) 0.540
FK506/CsA (%) 23 (72)/9 (28) 29 (58)/20 (42) 0.148
SCAR (%) 4 (12.5) 11 (22) 0.216
Table 1. Comparisons of baseline characteristics among the pa-
tients
LT, Liver Transplantation; KT, Kidney Transplantation; DD, Deceased
donor; LRD, Living donor; PRA, panel reactive antibody; FK506, tacro-
limus; CsA, cyclosporine; SCAR, subclinical acute rejection.CD25+ cells were analyzed using a Coulter EPICS XL (Beck-
man Coulter, Miami, FL, U.S.A.). Lymphocytes were gated
on the basis of light scatter characteristics and at least 10,000
events were obtained for each patient sample. The lympho-
cyte purity of ≥98% of gated populations was confirmed
with staining of a CD45-FITC antibody (Dinona).
ELISPOT assays
The Interleukin-10 ELISPOT assay was performed using a
commercial kit (eBioscience Co, San Diego, CA, U.S.A.) as
previously reported (11). Peripheral blood lymphocytes (PBLs)
were freshly isolated by Ficoll density gradient. PBLs from
the recipients (200,000 cells/well) in 100 μ L of culture medi-
um were placed in 96-well ELISPOT plates that were pre-
coated with capture anti-IL-10 antibody, and PBLs (200,000
cells/well) from donor lymphocytes. Stimulator cells were
used after 3000 rad (30 Gy) irradiation, and all assays were
performed under sterile conditions. Plates were then incubat-
ed overnight at 37℃. Following three washes with washing
buffer, a biotinylated detection antibody was added to the
wells (100 μ L/well), and the plates were incubated for 2 hr.
After an additional wash, anti-streptavidin horseradish per-
oxidase was added for 45 min at room temperature. After a
final wash, the plates were developed with aminoethylcarbazole
(10 mg/mL in N,N-dimethylformamide; Pierce Chemiclas,
Rockford, IL, U.S.A.), prepared in 0.1 M sodium acetate buffer
(pH 5.0) mixed with H2O2. The resulting spots were counted
with AID ELISPOT analyzer (Autoimmun Diagnostika,
Germany). 
Statistical analysis
The data were expressed as mean±SD or median and inter-
quartile ranges (IQR) (25-75th percentiles). For continuous
variables, statistical significance was assessed by Student’s t-
test or, if the variable deviated from a normal distribution,
by nonparametric tests (Mann-Whitney). The statistics were
performed with Windows SPSS 10.5. A two-tailed p value
of <0.05 was considered to be statistically significant.
RESULTS
The frequency of Tregs before transplantation
Fig. 1A shows the comparison of the frequency of Tregs
before transplantation in KT and LT recipients and in healthy
controls. The median frequencies of Tregs in KT recipients
and healthy controls were 4.2% (range 2.5-9.7%) and 2.7%
(1.6-5.7%), respectively, both of which were significantly
lower than that in LT recipients (9.0% [4.4-16.2%], p=0.01);
however, there was no significant difference between KT
recipients and healthy controls. 
We further compared the median frequencies of Tregs in
patients with different underlying diseases. There were no
significant differences based on the underlying disease in KT
patients (Fig. 1B). However, LT patients showed different
levels of Tregs depending on their underlying chronic liver
disease. The highest levels were observed in patients with
chronic hepatitis B and alcoholic cirrhosis (both groups p<
0.001 compared with healthy controls) (Fig. 1C).
The change in frequency of Tregs after transplantation
In kidney transplant recipients, the frequency of Tregs
decreased significantly after transplantation. After transplan-
tation, the median frequency of circulating Tregs was 2%
(1-3.6%) at one week, 1.6% (0.5-3.3%) at two weeks and
2.5% (1.7-3.7%) at eight weeks (all p<0.001 compared with
those before transplantation) (Fig. 2A). The frequencies of
circulating Tregs after LT showed a similar pattern but the
differences did not reach statistical significance when com-
pared with those before transplantation (Fig. 2B).


































Fig. 1. (A) Comparison of the frequency of circulating CD4
+CD25
+ T regulatory cells (Tregs) in healthy subjecrs (HS) and in patients with
end stage renal disease (ESRD) and chronic liver disease (CLD). The frequency of Tregs is expressed as a percentage of peripheral blood
mononuclear cells (PBMCs). Median, interquartile range (boxes) and range (whiskers) are shown. 
#denotes p values <0.01 compared
with CLD. *denotes p values <0.001 compared with HC. (B) Comparison of circulating Tregs frequencies based on the underlying dis-
ease in patients with ESRD. CGN, chronic glomerulonephritis; DM, diabetes mellitus; LN, lupus nephritis. (C) Comparison of circulating
Tregs frequencies based on the underlying disease in patients with CLD. Note the significantly increased Tregs frequency in alcoholic
cirrhosis and chronic hepatitis B compared with HC. *denotes p values <0.001. ALC, alcoholic liver cirrhosis; CHB, chronic hepatitis B;
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* *Association between frequency of Tregs and clinical
parameters
Fig. 3 shows the association between the frequency of cir-
culating Tregs and clinical parameters. The number of HLA
mismatches, donor origin, related vs. nonrelated donor, the
presence of panel-reactive antibodies and allograft dysfunc-
tion were not correlated with the frequency of Tregs (Fig. 3A-
E). Infectious complications such as BK virus and cytome-
galovirus infection also did not lead to any significant changes
in the level of Tregs (Fig. 3F, G). Only patients with subclin-
ical acute rejection in protocol biopsies had significantly dec-
reased frequencies of Tregs compared with those with no
detectable rejection (1.1% [0.2-1.8%] vs. 2.3% (0.6-4.7%),
p=0.026) (Fig. 3H). So we analyzed these clinical parameters
in recipients in whom protocol biopsies were performed (n=
42) (Table 2). There were no significant differences between
the two groups, except for donor source. The patients with
SAR showed high percentage of deceased donor compared
with patients without SAR (27% vs. 3%, p=0.049). 
The influence of immunosuppressants on the frequency
of Tregs
Fig. 4A-C shows the influence of different immunosuppres-
sants on the frequency of Tregs. The frequency of circulating
Tregs in the FK groups was higher than other groups before
transplantation (p<0.05) but significantly decreased after
renal transplantation (p<0.05). Similar finding was observed
in the CsA group. However, the mTOR group did not show
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≤3 (n=30) >3 (n=20) A
Fig. 2. (A) The sequential changes in the frequency of circulating CD4
+CD25
+ T regulatory cells (Tregs) before and after kidney transplan-
tation. Note the significant decrease in circulating Tregs during the early posttransplant period. (B) The serial measurement of CD4+CD25+
Tregs frequencies in liver transplant (LT) recipients. The frequency of Tregs is expressed as a percentage of peripheral blood mononu-
clear cells (PBMCs). Median, interquartile range (boxes) and range (whiskers) are shown. *denotes p values <0.001 compared with base-
line (pretransplant) level.
Fig. 3. The association between the frequency of circulating Tregs and clinical parameters (A-H) in kidney transplant recipients. The fre-
quency of Tregs is expressed as a percentage of peripheral blood mononuclear cells (PBMCs). Median, interquartile range (boxes) and
range (whiskers) are shown. Note that there is no significant association between circulating Tregs and clinical parameters (A-G) except
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*any significant difference of circulating Tregs before and after
transplantation. Frequencies were increased at eight weeks
after transplantation but the difference did not reach statis-
tical significance. 
We further evaluated whether the blood concentration of
the calcineurin inhibitors (CNIs), CsA and FK506, affected
the frequency of circulating Tregs. The patients with high
FK506 levels (≥10 ng/mL) had lower levels of Tregs than
those with low FK506 levels (<10 ng/mL) (Fig. 4D); how-
ever, the blood levels of CsA did not affect the level of Tregs
(Fig. 4E). 
IL-10 ELISPOT assay and Tregs
To explore whether the frequency of IL-10-secreting cells
determined by ELISPOT assay was related to the frequency
of Tregs, we performed an IL-10 ELISPOT assay in all kidney
transplant patients. The median frequencies of IL-10 secreting
cells, as determined by ELISPOT, were 95 (17-177), 12 (0-
92), 211 (16-345) and 75 (34-118) spots per 200,000 periph-
eral blood lymphocytes (spots/PBLs) before transplant and
at one, two and eight weeks after transplant, respectively. The
frequency of donor-specific IL-10 spots was not correlated
with the frequency of circulating Tregs before or after trans-
plantation. In addition, there were no differences in the fre-
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SAR, subclinical acute rejection; DD, Deceased donor; LRD, Living
donor; PRA, panel reactive antibody; FK groups, Basiliximab+Predni-
solone+tacrolimus+mycophenolate mofetil; CsA groups, Basiliximab+








Age (yr, mean±SD) 44±94 0 ±12 0.246
Male sex (%)  7 (64) 11 (26) 0.699
Donor 
Age (yr, mean±SD) 36±12 40±11 0.246
Male sex (%)  5 (46) 23 (74) 0.559
Donor source 0.049
LRD 8 (73) 30 (97)
DD 3 (27) 1 (3)
Number of HLA mismatch 3.9±1.5 3.1±1.6 0.176
PRA (+) 3 (27.3) 2 (6.5) 0.103
Immunosuppressants 0.445
FK groups 4 (36) 4 (13)
CsA groups 7(64) 18 (58)
CsA/mTORi groups - 9 (30)
CD4
+CD25
+ T cells (%) 1.1 (0.2-1.8) 2.3 (0.6-4.7)  0.026
Table 2. Comparison of clinical parameters in patients with or
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Fig. 4. Comparison of circulating Tregs frequencies based on type of immunosuppressant (A-C) and drug levels (D and E) in kidney trans-
plant recipients. A significant decrease in circulating Tregs was observed in the FK506 group (A, n=28), and the CsA group (B, n=12) but
not in the CsA/mTOR inhibitor group (C, n=10). Patients with a high blood level of FK506 (≥10 ng/mL, n=17) showed a lower frequency
of circulating Tregs than did patients with low blood levels of FK506 (<10 ng/mL, n=11) but blood levels of CsA did not affect circulating
Tregs. The frequency of Tregs is expressed as the percentage of peripheral blood mononuclear cells (PBMCs). Median, interquartile
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quencies of donor-specific IL-10 spots between patients with
and without subclinical acute rejection after KT (12.5 [0-
95] vs. 7 [0-67], 69 [16-188] vs. 75 [24-118], 121 [8-230]
vs. 454 [454-454] spots/PBLs at one, two and eight weeks
after transplant, respectively). 
DISCUSSION
The results of our study demonstrate that the frequency of
circulating Tregs during the early posttransplant period in
renal transplant recipients is affected by the type of immuno-
suppressant treatment and associated with subclinical acute
rejection. This finding suggests that circulating Tregs may
be used as a surrogate marker for assessing immune status
of renal transplant recipients during the early posttransplant
period.
The frequency of Tregs in patients with ESRD was not sig-
nificantly different from that in healthy controls (12), but
lower than that in patients with chronic liver diseases. The
reason for differences in frequency of Tregs between ESRD
and chronic liver diseases is unclear, but it may be related to
the underlying disease and organ specificity. Even in patients
with chronic liver diseases, frequencies of circulating Tregs
were different according to etiology: patients with chronic
Hepatitis B or alcoholic cirrhosis had higher frequencies of
circulating Tregs than did those with other liver diseases (13,
14). This finding suggests that an altered immune response
due to Hepatitis B virus infection or alcohol may increase the
Tregs frequency. 
We found that the frequency of circulating Tregs was sig-
nificantly decreased after kidney transplantation but not after
liver transplantation. This discrepancy between two organs
is not fully understood, but it may be explained by organ-
specific immunity between kidney and liver. It is generally
accepted that the liver transplant recipients have less immune
response (less acute rejection and more immune tolerance)
than kidney transplant recipients (15). This finding suggests
that higher frequency of circulating Tregs in liver transplant
recipients may be related to the less immune response. Anoth-
er consideration is the dose and type of immunosuppressants.
In our study, liver transplant recipients received less immuno-
suppression (lower dose of immunosuppressants and the small-
er number of anti-CD25 antibody) than patients of kidney
transplantation. Therefore, less immune suppression in liver
transplant recipients may be partly responsible for higher
frequency of circulating Tregs. 
To evaluate whether clinical parameters affect the frequen-
cy of Tregs, we evaluated the immunologic factors (the num-
ber of HLA mismatches, donor origin, related vs. nonrelat-
ed donor, presence of panel-reactive antibodies and acute rejec-
tion), infectious factors (BK virus and cytomegalovirus) and
allograft function (Presence of allograft dysfunction). The
results of our study revealed that the frequency of circulat-
ing Tregs has no significant association with these clinical
parameters except subclinical acute rejection which showed
low frequency of Tregs. This finding was consistent with recent
reports that showed decreases in circulating Tregs accompa-
ny allograft rejection in pediatric liver allograft recipients,
and the frequency of peripheral circulating Tregs was signif-
icantly decreased after the development of acute rejection in
liver transplantation (16, 17). The direct relationship between
circulating Tregs and acute rejection is not fully understood
in clinical practice, but animal study showed that transfer of
Tregs from long-term tolerant mice to allografted mice can
prevent rejection of transplanted allogeneic pancreatic islets
and skin (18, 19). Therefore, the frequency of circulating Tregs
may be used as a surrogate marker for predicting subclinical
acute rejection during the early posttransplant period. 
The activation of Tregs depends on the engagement of the
T-cell receptor and the presence of IL-2 signaling (20, 21).
Therefore, CNIs or anti-CD25 antibody may prevent the
generation and maintenance of Tregs by blocking IL-2 sig-
naling or receptor (22). Indeed, CNIs decrease FoxP3 mRNA
and protein expression in vitro (23, 24) and reduce the num-
ber of peripheral blood Tregs in renal transplant recipients
(25). The frequency of circulating Tregs decreased in patients
treated with CNI or anti-CD25 antibody, but it was difficult
to evaluate the influence of immunosuppressant on circulat-
ing Tregs separately because all patients received both CNIs
and anti-CD25 antibody. However, a high blood concentra-
tion of FK506 (≥10 ng/mL) was closely associated with a
lower frequency of Tregs. Therefore, we can at least conclude
that number of circulating Tregs is affected by blood level
of FK506. 
In contrast, mTOR inhibitors selectively expand regula-
tory T cells in vivo (26). Therefore, it is presumable that the
patients receiving mTOR inhibitors may have elevated cir-
culating Tregs. In this study, we found that combined treat-
ment of mTOR inhibitors (sirolimus/everolimus) and CsA
did not decrease circulating Tregs. This finding suggests that
mTOR inhibitors increase circulating Tregs, but direct effect
of mTOR inhibitors on number of circulating Tregs needs
to be evaluated. Thus, we cautiously conclude that mTOR
inhibitors may compensate the decreased circulating Tregs
caused by CsA. 
IL-10 is required for the generation and suppressor func-
tions of Tregs (6, 27). Boogaardt et al. (28) reported that more
IL-10 producing cells were found in patients with a stable
graft function than in those with rejection. Therefore, we
expected that the frequency of Tregs would have a close asso-
ciation with the frequency of IL-10 producing cells; however,
our study did not find any significant correlation between these
two factors. The reason for this lack of association between
IL-10 producing cells and Tregs is not clear, but it may be
related to the small proportion of circulating Tregs in the
ELISPOT assay. Further evaluation with selected Tregs may
be needed to define the association between circulating Tregsand IL-10.
It is widely accepted that Tregs play a pivotal role in toler-
ance induction (7). Therefore, an increase in circulating Tregs
may be beneficial to the grafted kidney in terms of immune
tolerance. The results of our study revealed that the frequen-
cy of circulating Tregs is significantly reduced by strong
immunosuppressants such as CsA or FK506, and that a high
blood concentration of FK506 further reduced the frequen-
cy of circulating Tregs. The decrease in frequency of Tregs
seen at one and two weeks after renal transplant gradually
disappeared by eight weeks after transplant. This finding
suggests that high doses of CNIs at the time of transplanta-
tion prevent the development of Tregs (29) and that tapering
of CNI may prevent a further decrease in circulating Tregs.
Thus, treatment with CsA or FK506 in the early posttrans-
plant period should be used cautiously and high doses of
CNIs should be avoided because it may inhibit the develop-
ment of immune tolerance. Further evaluation of the long-
term effect of CNIs on circulating Tregs and the optimal
frequency of circulating Tregs during the early transplant
period in kidney transplantation is needed.
One could argue that FK506 may increase subclinical acute
rejection by decreasing circulating Tregs because the results
of our study revealed that a lower frequency of circulating
Tregs was associated with subclinical acute rejection. In our
center, we use FK506 in immunologically moderate to high
risk patients such as those with high numbers of HLA mis-
matches, nonrelated or deceased donors and in retransplant-
ed recipients. Therefore, these patients have many risk fac-
tors for acute rejection and, indeed, the incidence of subclini-
cal acute rejection in protocol biopsies in the FK506 group
was not increased compared with CsA groups. Therefore, an
association between FK506 treatment and subclinical acute
rejection in terms of circulating Tregs may be excluded.
In summary, monitoring of circulating Tregs in peripheral
blood is helpful for evaluating the immune status of kidney
transplant recipients during the early posttransplant period.
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